Compare ARK Fintech Innovation ETF (ARKF) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Citius Pharmaceuticals Inc — how do they compare? ARK Fintech Innovation ETF trades at $41.45, while Citius Pharmaceuticals Inc trades at $0.58 (market cap $16.00M). The key difference: ARK Fintech Innovation ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKF | CTXR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $1.82 |
52-Week Low | $36.14 | $0.53 |
Market Cap | — | $16.00M |
Enterprise Value | — | $12.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.
The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.
CTXR trades at $0.5827, up 3.81% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported a net loss of $37.43M in 2025 with a -823.34% net margin, though revenue reached $5.6M in H1 2026 from LYMPHIR commercialization. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO 2026.
Outlook remains speculative with high cash burn offset by financing; analyst consensus is 83% buy but financial sustainability depends on successful drug adoption. Key risks include clinical trial outcomes, dilution from recent $5M offering, and achieving profitability amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
